- Home
- MICC vs QGEN Comparison
MICC vs QGEN Comparison
Compare MICC & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$16.73
HOLD
Current Price
$50.49
Company Overview
Basic Information| Metric | MICC | QGEN |
|---|---|---|
| Founded | N/A | 1986 |
| Country | Netherlands | Netherlands |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 10.2B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | MICC | QGEN |
|---|---|---|
| Price | $16.73 | $50.49 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 9 |
| Target Price | N/A | ★ $51.30 |
| AVG Volume (30 Days) | 1.3M | ★ 3.6M |
| Earning Date | 05-13-2026 | 02-04-2026 |
| Dividend Yield | N/A | ★ 4.78% |
| EPS Growth | N/A | ★ 409.76 |
| EPS | 0.56 | ★ 2.04 |
| Revenue | ★ $9,287,307,741.00 | $2,089,999,000.00 |
| Revenue This Year | $2.81 | $7.75 |
| Revenue Next Year | $4.10 | $6.13 |
| P/E Ratio | $29.57 | ★ $24.69 |
| Revenue Growth | ★ 7.33 | 5.65 |
| 52 Week Low | $14.45 | $39.61 |
| 52 Week High | $19.93 | $57.82 |
Technical Indicators
Market Signals| Indicator | MICC | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 45.98 | 57.39 |
| Support Level | $15.97 | $50.71 |
| Resistance Level | $19.93 | $51.71 |
| Average True Range (ATR) | 0.43 | 1.19 |
| MACD | -0.14 | -0.39 |
| Stochastic Oscillator | 23.02 | 48.35 |
Price Performance
Historical Comparison MICC
QGEN
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).